Table 1 Baseline characteristics of men in NDR diagnosed with prostate cancer and/or used GnRH between 2006 and 2016 and their matched comparison
PCa + GnRH exposure cohort | GnRH exposure cohort | |||
|---|---|---|---|---|
PCa men (N = 5714) | No PCa men (N = 28,445) | PCa using GnRH men (N = 692) | PCa without using GnRH men (N = 3460) | |
Patients characteristics | ||||
Age (year), No. (%) | ||||
< 60 | 233 (4.1) | 1071 (3.8) | 8 (1.2) | 60 (1.7) |
60–69 | 1886 (33.0) | 8034 (28.2) | 101 (14.6) | 805 (23.3) |
70–79 | 2608 (45.6) | 12,984 (45.6) | 304 (43.9) | 1730 (50.0) |
80+ | 987 (17.3) | 6356 (22.3) | 279 (40.3) | 865 (25.0) |
Education level, No. (%) | ||||
Low | 2340 (41.0) | 12,231 (43.0) | 308 (44.5) | 1333 (38.5) |
Middle | 2755 (48.2) | 13,172 (46.3) | 297 (42.9) | 1678 (48.5) |
High | 570 (10.0) | 2686 (9.4) | 82 (11.8) | 432 (12.5) |
Missing | 49 (0.9) | 356 (1.3) | 5 (0.7) | 17 (0.5) |
Civil status, No. (%) | ||||
Married | 3708 (64.9) | 17,582 (61.8) | 444 (64.2) | 2248 (65.0) |
Not married (+Divorced/Widower/missing) | 2006 (35.1) | 10,863 (38.2) | 248 (35.8) | 1212 (35.0) |
CCI, No. (%) | ||||
0 | 2413 (42.2) | 10,319 (36.3) | 197 (28.5) | 942 (27.2) |
1 | 1348 (23.6) | 6494 (22.8) | 174 (25.1) | 1014 (29.3) |
2 | 765 (13.4) | 4246 (14.9) | 109 (15.8) | 538 (15.5) |
3+ | 1188 (20.8) | 7386 (26.0) | 212 (30.6) | 966 (27.9) |
Smoking, No. (%) | ||||
No | 4581 (80.2) | 22,273 (78.3) | 524 (75.7) | 2683 (77.5) |
Yes | 553 (9.7) | 2912 (10.2) | 51 (7.4) | 267 (7.7) |
Missing | 580 (10.2) | 3260 (11.5) | 117 (16.9) | 510 (14.7) |
Times of at least 60 min physical activity in 7 days, No. (%) | ||||
Daily | 573 (10.0) | 3452 (12.1) | 98 (14.2) | 380 (11.0) |
3–5 times a week | 500 (8.8) | 2486 (8.7) | 69 (10.0) | 268 (7.7) |
1–2 times a week | 902 (15.8) | 4261 (15.0) | 96 (13.9) | 503 (14.5) |
Less than once a week | 1016 (17.8) | 4786 (16.8) | 104 (15.0) | 629 (18.2) |
Never | 1531 (26.8) | 6919 (24.3) | 140 (20.2) | 784 (22.7) |
Missing | 1192 (20.9) | 6541 (23.0) | 185 (26.7) | 896 (25.9) |
BMI (kg/m2), No. (%) | ||||
< 25 | 969 (17.0) | 4668 (16.4) | 111 (16.0) | 610 (17.6) |
25–29 | 2509 (43.9) | 11,845 (41.6) | 291 (42.1) | 1507 (43.6) |
30–34 | 1342 (23.5) | 6677 (23.5) | 150 (21.7) | 731 (21.1) |
35–39 | 353 (6.2) | 1961 (6.9) | 39 (5.6) | 187 (5.4) |
40+ | 91 (1.6) | 612 (2.2) | 15 (2.2) | 52 (1.5) |
Missing | 450 (7.9) | 2682 (9.4) | 86 (12.4) | 373 (10.8) |
Number of visits, No. (%) | ||||
3–9 | 3794 (66.4) | 18,879 (66.4) | 504 (72.8) | 2520 (72.8) |
10–19 | 1520 (26.6) | 7578 (26.6) | 151 (21.8) | 755 (21.8) |
20–29 | 315 (5.5) | 1567 (5.5) | 29 (4.2) | 145 (4.2) |
30+ | 85 (1.5) | 421 (1.5) | 8 (1.2) | 40 (1.2) |
T2DM status | ||||
Duration of T2DM (Years), No. (%) | ||||
< 10 | 2751 (48.1) | 12,755 (44.8) | 320 (46.2) | 1703 (49.2) |
10–19 | 1939 (33.9) | 10,149 (35.7) | 222 (32.1) | 1139 (32.9) |
20–29 | 530 (9.3) | 3123 (11.0) | 78 (11.3) | 310 (9.0) |
30+ | 158 (2.8) | 921 (3.2) | 23 (3.3) | 90 (2.6) |
Missing | 336 (5.9) | 1497 (5.3) | 49 (7.1) | 218 (6.3) |
HbA1c (mmol/mol), No. (%) | ||||
< 40 | 330 (5.8) | 1484 (5.2) | 63 (9.1) | 221 (6.4) |
40–57 | 3673 (64.3) | 16,834 (59.2) | 434 (62.7) | 2181 (63.0) |
58–69 | 1093 (19.1) | 6045 (21.3) | 119 (17.2) | 642 (18.6) |
70–79 | 324 (5.7) | 2122 (7.5) | 37 (5.3) | 187 (5.4) |
80–89 | 131 (2.3) | 929 (3.3) | 14 (2.0) | 98 (2.8) |
90+ | 87 (1.5) | 612 (2.2) | 12 (1.7) | 61 (1.8) |
Missing | 76 (1.3) | 419 (1.5) | 13 (1.9) | 70 (2.0) |
Primary treatment of T2DM, No. (%) | ||||
Insulin | 3420 (59.9) | 10,246 (36.0) | 237 (34.2) | 1080 (31.2) |
Oral Hypoglycaemics | 426 (7.5) | 2330 (8.2) | 46 (6.6) | 276 (8.0) |
Diet controlled | 1868 (32.7) | 15,869 (55.8) | 409 (59.1) | 2104 (60.8) |
PCa status | ||||
PCa diagnosis, No. (%) | ||||
No PCa | – | 28,445 (100.0) | – | – |
PCa | 5714 (100.0) | – | 692 (100.0) | 3460 (100.0) |
Using GnRH, No. (%) | ||||
No PCa | – | 28,445 (100.0) | – | – |
No | 4274 (74.8) | – | – | 3460 (100.0) |
Yes | 1400 (25.2) | – | 692 (100.0) | – |
PCa risk category, No. (%) | ||||
No PCa | – | 28,445 (100.0) | ||
Low risk | 1122 (19.8) | – | 145 (21.0) | 1437 (41.5) |
Intermediate risk | 1838 (32.2) | – | 229 (33.1) | 1272 (36.8) |
High risk | 1531 (26.8) | – | 232 (33.5) | 533 (15.4) |
Regional metastasises | 389 (6.8) | – | 42 (6.1) | 56 (1.6) |
Distance metastasises | 650 (11.4) | – | 32 (4.6) | 39 (1.1) |
Missing data | 184 (3.2) | – | 12 (1.7) | 123 (3.6) |